Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer
Open Access
- 5 April 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 882
Abstract
Objectives: Pancreatic cancer remains a therapeutic challenge due to its immunosuppressive microenvironment and treatment resistance. This study aimed to develop a novel recombinant oncolytic vaccinia virus (VVL-GL7) co-expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-7 (IL-7), designed to enhance anti-tumor immunity and synergize with immune checkpoint inhibitors. Methods: VVL-GL7 was constructed through CRISPR/Cas9-mediated knockout of TK and A49 genes, combined with the simultaneous insertion of dual cytokine-encoding cassettes. Anti-tumor efficacy was evaluated in vitro and in vivo using C57BL/6 mouse and Syrian hamster pancreatic cancer models. Comprehensive immune profiling evaluated CD8+ T-cell and macrophage infiltration dynamics while simultaneously assessing memory T-cell differentiation patterns using flow cytometry. Preclinical combination studies of VVL-GL7 and the PD-1 immune checkpoint inhibitor were systematically evaluated in a syngeneic pancreatic cancer model. Results: VVL-GL7 exhibited potent oncolytic activity, inducing significant tumor regression in both preclinical models. VVL-GL7 therapy significantly augmented CD8+ T-cell and macrophage infiltration within the tumor microenvironment, while concomitantly driving memory T-cell differentiation. The synergistic effects of VVL-GL7 and the PD-1 blockade further improved therapeutic outcomes, resulting in significantly higher tumor remission rates compared to monotherapy and achieving complete tumor regression in pancreatic cancer models. Conclusions: VVL-GL7 reprograms the immunosuppressive tumor microenvironment and synergizes with anti-PD-1 antibodies to overcome resistance in pancreatic cancer.Keywords
Funding Information
- Joint Fund for Science and Technology Research and Development of Henan province (242301420013)
- National Key Research and Development Program of China (2019YFC1316101)
- National Natural Science Foundation of China (81872486)
This publication has 65 references indexed in Scilit:
- Integrating innate and adaptive immunity in oncolytic virus therapyTrends in Cancer, 2023
- Pre-treatment of oncolytic reovirus improves tumor accumulation and intratumoral distribution of PEG-liposomesJournal of Controlled Release, 2023
- The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesCell, 2022
- Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapyPharmacological Research, 2020
- Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironmentCancer Immunology, Immunotherapy, 2020
- Oncolytic viruses: a new class of immunotherapy drugsNature Reviews Drug Discovery, 2015
- Going viral with cancer immunotherapyNature Reviews Cancer, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamsterCancer Gene Therapy, 2009
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialThe Lancet Oncology, 2008